Day: March 2, 2026

BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval. Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs. In December 2025, zurletrectinib received approval for the treatment of adult and adolescent patients (aged 12 years...

SHENZHEN, China, March 02, 2026 (GLOBE NEWSWIRE) — Pony AI Inc. (“Pony.ai” or the “Company”) (NASDAQ: PONY; HKEX: 2026), a global leader in achieving large-scale mass production and commercialization of autonomous driving technology, today announced that it has achieved seventh-generation (“Gen-7”) Robotaxi unit economics (“UE”) breakeven1 in Shenzhen. This milestone underscores Pony.ai’s capability to realize a sustainable business model, laying a solid foundation to accelerate scale-up over a multi-year horizon. Driven by surging user demand and optimized operational efficiency, Pony.ai’s commercial operations in Shenzhen have delivered outstanding results. As of February 28, the one-month daily average net revenue per Gen-7 Robotaxi has reached RMB338, with a daily average of 23 orders per vehicle. These figures demonstrate...